Tumor‐educated platelet <scp>SNORD55</scp> as a potential biomarker for the early diagnosis of non‐small cell lung cancer

Dong, Xiaohan; Song, Xianrang; Ding, Shanshan; Yu, Miao; Shang, Xiaoling; Wang, Kangyu; Chang, Ming Chau; Xie, Li

doi:10.1111/1759-7714.13823

Cited by 27 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 34 SNORD63 and SNORD96A are stable in plasma and urinary sediment, and also potentially play as noninvasive early biomarkers for clear cell renal cell carcinoma. 30 Compared with normal people, downregulated tumor-educated platelets SNORD55 is significantly related to TNM stage I/II patients with lung adenocarcinoma and lung squamous cell carcinoma, 51 and increased plasma SNORD83A was related to tumor size. 52 Tumor-educated platelets SNORD55 and plasma SNORD83A can distinguish NSCLC patients, even early NSCLC from controls with sufficient specificity and sensitivity.…”

Section: Discussionmentioning

confidence: 99%

The Potential Role of Small Nucleolar RNAs in Cancers – An Evidence Map

Zhang

et al. 2022

IJGM

View full text Add to dashboard Cite

Purpose Cancer seriously endangers human health in every country of the world. New evidence shows that small nucleolar RNAs play important roles in tumorigenesis. Herein, we created this evidence map to systematically assess the impact of dysregulated snoRNAs on cancers. Methods We searched four databases to February 2022 using the keywords, “carcinoma”, “neoplasms”, “tumor”, “cancer”, “snoRNA”, and “small nucleolar rna”. The research data were independently screened by two reviewers. Bubble plot, mind map, heatmap were used to depict the relationship between snoRNAs and cancers. Results In total, 102 studies met the inclusion criteria and were analyzed in this evidence map. In this study, we found that dysregulated snoRNAs were statistically associated with the clinicopathological characteristics of cancer patients, and affected tumor cell phenotypes. Abnormally expressed snoRNAs were associated with poor survival in cancer patients. Current research confirmed that snoRNAs have good diagnostic efficiency for cancers. snoRNAs could modulate biological processes and signaling pathways of different cancer cells by altering rRNA, regulating mRNA, and recruiting protein factors. Conclusion Taken all together, ectopic snoRNAs may serve as new biomarkers for clinical assessment, diagnostic, prognostic prediction of cancer patients, and provide a potential therapeutic strategy for cancer treatment. This article provided a visual analysis of existing evidence on snoRNAs and cancers, which can offer useful information for different researchers interested in snoRNAs.

show abstract

Section: Discussionmentioning

confidence: 99%

The Potential Role of Small Nucleolar RNAs in Cancers – An Evidence Map

Zhang

et al. 2022

IJGM

View full text Add to dashboard Cite

show abstract

“…Lung cancer is one of the most common malignant tumors in the world 33 . To date, there are few effective and clinically feasible methods for early diagnosis and screening of lung cancer 34–37 . Although histology and cytology are the gold standard for the diagnosis of lung cancer, patients are often in advanced stages at the time of diagnosis by histology and cytology examination.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta‐analysis update

Zhou

Lü

et al. 2021

Thoracic Cancer

View full text Add to dashboard Cite

Objective To evaluate the diagnostic performance of short state homeobox 2 (SHOX2) promoter methylation as biomarker for lung cancer identification through aggregating the open published data. Methods We did an electronic search in Pubmed, EMBASE, Ovid, Web of Science, Google Scholar, and the China National Knowledge Infrastructure (CNKI) to identify the publications related to SHOX2 promoter methylation and lung cancer. The diagnostic performance of sensitivity (SEN), specificity (SPE), odds ratio (DOR), and summary receiver operating characteristic (SROC) cure were aggregated by fixed or random effect model. Fagan's nomogram was used to investigate the post‐test diagnostic probability. Deek's funnel plot and line regression test was applied to evaluate the publication bias. Results In total, 18 clinical studies about SHOX2 promoter methylation and lung cancer were included in the meta‐analysis. The combined diagnostic SEN, SPE, DOR were 0.63 (95% CI = 0.54–0.70), 0.91 (95% CI = 0.87–0.94), and 16.84 (95% CI = 11.18–25.36) in random effect model respectively. The pooled area under the curve (AUC) of SROC was 0.88 (95% CI = 0.84–0.90). The post‐test probability of lung cancer was 88% and 29% when SHOX2 methylated and unmethylated in humoral components given a pre‐test probability of 50%. Deek's funnel plot and regression test indicated no publication bias (p = 0.62). Conclusion SHOX2 promoter methylation in humoral components may be a potential biomarker for lung cancer diagnosis with relative high diagnostic specificity.

show abstract

“…Dong X et al used low-speed centrifugation to separate platelets from plasma and performed quantitative polymerase chain reaction (qPCR) to detect small nucleolar RNA SNORD55. 92 The results showed that, compared with healthy controls, SNORD55 in the TEP of NSCLC patients was significantly lower, especially in early-stage patients. Importantly, they verified that TEP SNORD55 can be used as a promising biomarker for NSCLC.…”

Section: Teps May Facilitate Blood-based Tumour Diagnosismentioning

confidence: 91%

Platelets: The Emerging Clinical Diagnostics and Therapy Selection of Cancer Liquid Biopsies

Meng¹,

Sun²,

Yang³

et al. 2021

OTT

View full text Add to dashboard Cite

Due to the inherent molecular heterogeneity of metastatic tumours and the dynamic evolution ability of tumour genomes, tumour tissues obtained through biopsy and other methods cannot capture all of the features of tumour genomes. A new diagnostic concept called "liquid biopsy" has received widespread attention in recent years. Liquid biopsy has changed the clinical practice of oncology and is widely used to guide targeted drug utilization, monitor disease progression and track drug resistance. The latest research subject in liquid biopsy is platelets. Platelets originate from multifunctional haematopoietic stem cells in the bone marrow haematopoietic system. They are small cells from the cytoplasm of bone marrow megakaryocytes. Their main physiological functions are to participate in the processes of physiological haemostasis and coagulation. Tumour cells transfer biomolecules (such as RNA) to platelets through direct contact and release of exosomes, which changes the platelet precursor RNA. Under the stimulation of tumour cells and the tumour microenvironment, platelet precursor mRNA is spliced into mature RNA and converted into functional protein to respond to external stimuli, forming tumoureducated platelets (TEPs). The detection of TEPs in the peripheral blood of patients is expected to be used in clinical tumour diagnosis. This emerging liquid biopsy method can replace and supplement the current tumour detection methods. Further research on the role of platelets in tumour diagnosis will help provide a novel theoretical basis for clinical tumour diagnosis.

show abstract

Tumor‐educated platelet SNORD55 as a potential biomarker for the early diagnosis of non‐small cell lung cancer

Cited by 27 publications

References 27 publications

The Potential Role of Small Nucleolar RNAs in Cancers – An Evidence Map

The Potential Role of Small Nucleolar RNAs in Cancers – An Evidence Map

Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta‐analysis update

Platelets: The Emerging Clinical Diagnostics and Therapy Selection of Cancer Liquid Biopsies

Contact Info

Product

Resources

About